

# **REBLOZYL<sup>®</sup> (luspatercept)**

## **Patient Card**

(For women of childbearing potential)

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA.

### **Patient Information**

REBLOZYL (luspatercept) should not be used during pregnancy and for 3 months before getting pregnant. REBLOZYL may cause harm to your unborn baby.

**Do not use** REBLOZYL if you are pregnant or breast-feeding, or could become pregnant and are not using at least one highly effective method of birth control.

- Before starting treatment with REBLOZYL:
  1. You must have a negative pregnancy test verified by your prescriber.
  2. You must discuss effective methods of birth control with your doctor and use of at least one highly effective method of birth control while taking REBLOZYL and for at least 3 months after stopping treatment with REBLOZYL.
- A pregnancy test must be repeated at suitable intervals.
- Tell your doctor right away if you are pregnant or think you might be pregnant during treatment with REBLOZYL or for 3 months after stopping REBLOZYL.

Please see the back of this reminder card for your prescriber's contact information.

For more information about the effects and side effects of REBLOZYL, please refer to the Local Patient Information Leaflet for REBLOZYL.

## **I have been prescribed REBLOZYL**

### **Important Contact Information**

My healthcare professional who prescribed REBLOZYL:

Name: \_\_\_\_\_

Office phone number: \_\_\_\_\_

Institution address: \_\_\_\_\_

\_\_\_\_\_

**For reporting any suspected adverse reactions via the national reporting system :**

**Bristol Myers Squibb, Saudi Arabia:**

At: [medinfo.saudiarabia@bms.com](mailto:medinfo.saudiarabia@bms.com)

or call: 800 844 7710

**The National Pharmacovigilance Centre (NPC)**

**Saudi Food and Drug Authority (SFDA):**

SFDA call center: 19999

Toll free phone: 8002490000

E-mail: [npc.drug@sfda.gov.sa](mailto:npc.drug@sfda.gov.sa)

Website: <http://ade.sfda.gov.sa/>

Fax: +966-11-2057662